Journal
BREAST CARE
Volume 11, Issue 3, Pages 167-173Publisher
KARGER
DOI: 10.1159/000447284
Keywords
Breast cancer; Cyclin-dependent kinase; Palbociclib; Abemaciclib; Ribociclib
Categories
Funding
- Lilly
- Novartis
- Pfizer
Ask authors/readers for more resources
Clinical and preclinical data support a significant role for inhibitors of the cyclin-dependent kinases (CDKs) 4 and 6 in the treatment of patients with breast cancer. Recently, based on data showing improvement in progression-free survival, the use of palbociclib (Ibrance; Pfizer, Inc.) in combination with endocrine agents was approved to treat patients with hormone receptor-positive advanced disease. Importantly, 2 other CDK4/6 inhibitors, abemaciclib (LY2835219; Lilly) and ribociclib (LEE011; Novartis), are in the late stage of clinical development. In this review, we will focus on clinical data on these 2 new drugs, highlighting their differences compared to palbociclib in terms of single-agent activity, central nervous system penetration, and common adverse events. In addition, we will present the ongoing clinical trials and discuss future directions in the field. (C) 2016 S. Karger GmbH, Freiburg
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available